Immunotherapy of melanoma

Giorgio Parmiani; Chiara Castelli; Licia Rivoltini; Chiara Casati; Glenn A. Tully; Luisa Novellino; Andrea Patuzzo; Diego Tosi; Andrea Anichini; Mario Santinami

doi:10.1016/j.semcancer.2003.09.001

Immunotherapy of melanoma

Giorgio Parmiani, Chiara Castelli, Licia Rivoltini, Chiara Casati, Glenn A. Tully, Luisa Novellino, Andrea Patuzzo, Diego Tosi, Andrea Anichini, Mario Santinami

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma.

Original language	English
Pages (from-to)	391-400
Number of pages	10
Journal	Seminars in Cancer Biology
Volume	13
Issue number	6
DOIs	https://doi.org/10.1016/j.semcancer.2003.09.001
Publication status	Published - Dec 2003

Keywords

Adoptive immunotherapy
Antigens
Melanoma
Vaccination

ASJC Scopus subject areas

Cancer Research

Access to Document

10.1016/j.semcancer.2003.09.001

Cite this

@article{e13b85a5f4d24b06b9d39a2fda147444,

title = "Immunotherapy of melanoma",

abstract = "The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma.",

keywords = "Adoptive immunotherapy, Antigens, Melanoma, Vaccination",

author = "Giorgio Parmiani and Chiara Castelli and Licia Rivoltini and Chiara Casati and Tully, {Glenn A.} and Luisa Novellino and Andrea Patuzzo and Diego Tosi and Andrea Anichini and Mario Santinami",

year = "2003",

month = dec,

doi = "10.1016/j.semcancer.2003.09.001",

language = "English",

volume = "13",

pages = "391--400",

journal = "Seminars in Cancer Biology",

issn = "1044-579X",

publisher = "Academic Press",

number = "6",

}

TY - JOUR

T1 - Immunotherapy of melanoma

AU - Parmiani, Giorgio

AU - Castelli, Chiara

AU - Rivoltini, Licia

AU - Casati, Chiara

AU - Tully, Glenn A.

AU - Novellino, Luisa

AU - Patuzzo, Andrea

AU - Tosi, Diego

AU - Anichini, Andrea

AU - Santinami, Mario

PY - 2003/12

Y1 - 2003/12

N2 - The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma.

AB - The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma.

KW - Adoptive immunotherapy

KW - Antigens

KW - Melanoma

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=10744228405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228405&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2003.09.001

DO - 10.1016/j.semcancer.2003.09.001

M3 - Article

C2 - 15001157

AN - SCOPUS:10744228405

SN - 1044-579X

VL - 13

SP - 391

EP - 400

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

IS - 6

ER -

Immunotherapy of melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this